Audio

AHRQ identifies interventions, drugs that best target diabetic neuropathy

Author and Disclosure Information

Which interventions are linked with fewer amputations? Which ones are best for preventing ulcers? And which 2 drugs have the best evidence to support their use in treating the symptoms of this painful condition? Listen to this month’s audiocast and find out.


 

Recommended Reading

IDegLira equals basal-bolus insulin in HbA1c, lowers hypoglycemia risk
MDedge Family Medicine
ODYSSEY: Alirocumab improves lipids but not glycemic targets in 2DM
MDedge Family Medicine
DURATION-8: Exenatide/dapagliflozin efficacy holds up at 1 year
MDedge Family Medicine
SPRINT: Intensive BP control cut cardiovascular risk in patients with prediabetes
MDedge Family Medicine
FDA advisory committee supports new CV liraglutide indication
MDedge Family Medicine
Oral insulin matches glargine in phase II trial
MDedge Family Medicine
Nocturia and sleep apnea
MDedge Family Medicine
LEADER post hoc analysis: Mechanism behind liraglutide’s cardioprotective effects unclear
MDedge Family Medicine
Red flags for type 2 diabetes seen 25 years before diagnosis
MDedge Family Medicine
Effect of Non–Insulin-Based Glucose-Lowering Therapies on Cardiovascular Outcomes in Patients With Type 2 Diabetes
MDedge Family Medicine